<DOC>
	<DOC>NCT01847118</DOC>
	<brief_summary>This study is to assess the safety, tolerability and pharmacokinetics of single dose and multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with advanced or metastatic solid tumors. The secondary objective is to explore the preliminary anti-tumor effects.</brief_summary>
	<brief_title>A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically or cytologically confirmed advanced or metastatic malignant solid tumors; Patients failed the standard antitumor therapy or don't have standard regimen; At least one measurable lesion; At least 4 weeks from the last chemotherapy, 6 weeks from mitomycin, and nitrosourea treatment. If patients received antitumor biological products, at least four t1/2 of washout period is needed; Toxicity from previous treatment has to restore to ≤ grade 1 (NCI CTC4.0); ECOG performance status 01; Life expectancy ≥ 3 months; Adequate hematologic function: ANC ≥ 1.5 × 10^9 /L, HB ≥ 90 g /L (blood transfusion allowed), PLT ≥ 100 × 10^9 /L; Adequate hepatic function: ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN, TBIL ≤ 1.5 × ULN (patients with liver metastases ALT ≤ 5 × ULN, AST ≤ 5 × ULN, TBIL ≤ 3 × ULN); Adequate renal function: creatinine ≤ 1 × ULN; Coagulation function: INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN; Patients of childbearing potential (male and female) must agree to use reliable methods of contraception until at least 12 weeks after the last dose. HCV, TP or HIV antibody positive; Previously received antiVEGF protein drugs, such as bevacizumab; Histologically proven squamous cell lung cancer or squamous cell carcinoma of the head and neck; Active hepatitis B infection; Evidence of serious infection; Symptomatic brain metastases; Patients with proteinuria at screening (urine protein ≥ 1+); History of abdominal fistula, gastrointestinal perforation, abdominal abscess within 6 months prior to enrollment; Serious nonhealing wounds, ulcers or fractures; Major surgery (excluding biopsy) or significant trauma within 4 weeks prior to enrollment; Active bleeding within 3 months prior to enrollment; Bleeding diathesis or coagulation disorder; History of arterial or venous thrombosis; History of myocardial infarction or stroke within 6 months prior to enrollment; Unstable angina, congestive heart failure, New York Heart Association (NYHA) class II heart failure, uncontrollable arrhythmia, uncontrolled hypertension (systolic blood pressure&gt; 150 mmHg and/or diastolic blood pressure&gt; 100 mmHg); Pregnant and lactating women; Known allergies to any excipient in the study drug; Patients with alcohol or drug dependence; Participation in other clinical trials within 4 weeks before enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>